Source comparison
CJC-1295 no DAC & Ipamorelin: Route Comparison
The following table summarizes the practical differences between administration routes for CJC-1295 no DAC & Ipamorelin, with specific attention to taste, bioavailability, and suitability for research contexts. Subcutaneous Injection None (peptide does not con
This comparison does not assign a generated winner or score.
- The following table summarizes the practical differences between administration routes for CJC-1295 no DAC & Ipamorelin, with specific attention to taste, bioavailability, and suitability for research contexts.
- Subcutaneous Injection
- None (peptide does not contact oral mucosa)
- ~95–100%
- 10–20 minutes
- Optimal. Standard route for GH secretagogue protocols
- Subcutaneous injection is the gold standard for CJC-1295 no DAC & Ipamorelin research due to near-complete bioavailability, predictable pharmacokinetics, and elimination of taste as a compliance factor.
- Sublingual
- Bitter, metallic, chemically astringent
- 10–30% (estimated; highly variable)
- 5–15 minutes
- Experimental only. Requires taste masking and dose adjustment
- Sublingual administration is limited by enzymatic degradation in saliva, low bioavailability, and poor taste tolerability. Suitable only for exploratory protocols investigating mucosal absorption.
- Oral (Swallowed)
- Bitter if not encapsulated; minimal taste if encapsulated
- <5% (near-zero without protection)
- Not applicable (degraded before absorption)
- Not recommended. Extensive formulation work required
- Oral administration is not viable for unmodified CJC-1295 no DAC & Ipamorelin due to gastric acid and protease degradation. Encapsulation strategies have been explored in research but do not achieve therapeutic bioavailability.